Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2009 and provided an update on its progress.
“I am pleased with the results and success we demonstrated on a number of fronts this past year despite operating in a very challenging economic climate”
2009 highlights include:
- Closing a Stem Cell agreement with Novartis Pharmaceuticals for an upfront payment of $3 million and potential technology transfer milestone payments totaling another $1 million (with total potential payments from the deal that could exceed $50 million);
- Securing the first milestone payment from Novartis related to the stem cell transaction of $0.5 million;
- Strengthening the management team, including the hiring of a highly qualified Senior VP of Clinical Development & Regulatory Affairs;
- Completing the TERMS Phase IIb clinical study analysis, which demonstrated that Tovaxin is safe and well tolerated with promising efficacy across key clinical endpoints including Annualized Relapse Rate and disability (EDSS);
- Closing two financings: $5.1 million in gross proceeds from a registered direct offering and $1.3 million in gross proceeds from a private placement of secured notes; and
- Presentation of Tovaxin® TERMS Phase IIb clinical data at the American Academy of Neurology (AAN) 61st annual meeting in Seattle, WA.
“I am pleased with the results and success we demonstrated on a number of fronts this past year despite operating in a very challenging economic climate,” commented Neil K. Warma, President and Chief Executive Officer of Opexa. “The company showed resolve and commitment throughout 2009 and finished the year competitively having strengthened its balance sheet and having positioned Tovaxin as perhaps one of the more promising treatments in development for MS. The pivotal point in the year was the completion of the stem cell transaction with Novartis. This alone contributed an immediate $3 million upfront payment and positioned us as eligible for future clinical and sales milestone payments in addition to future royalties on net sales of products developed from the use of the technology.”
“We finished the year with approximately $8.2 million in cash and cash equivalents which, at the current level of monthly burn of approximately $300,000, provides us with sufficient capital beyond 2010. Our focus over the next 6-12 months will be preparing for Tovaxin’s next clinical study, advancing regulatory and manufacturing activities and continuing our ongoing discussions with potential strategic partners regarding the further development of Tovaxin. Strengthening the Opexa team in 2009 through key internal hires and the addition of world class consultants was an important step in positioning Tovaxin for continued clinical development,” added Mr. Warma.
Year Ended December 31, 2009 Financial Results
Opexa reported no revenues in the year ended December 31, 2009 or in the comparable prior-year period.
Research and development expenses were $2,107,833 for 2009, compared with $8,388,734 for 2008. The decrease in expenses was primarily due to a decrease in activities related to the Phase IIb clinical trial for Tovaxin which was completed in 2008, closing the extension trial, a reduction in staff and a reduction in stock compensation expense.